Navigation Links
Uroplasty Reports Results for Second Quarter FY2010

MINNEAPOLIS, Nov. 2 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the second fiscal quarter ended September 30, 2009.

"Our team continues to execute our strategy for the current fiscal year by growing U.S. Macroplastique sales and maximizing the potential for gaining a unique CPT code for Urgent PC® treatments," said David Kaysen, President & CEO. "During the quarter, we learned that a manuscript of the results from the SUmiT Trial has been recommended for publication in The Journal of Urology® and is tentatively scheduled to appear in the April 2010 issue. This study reports on a 220-subject, multicenter, randomized, controlled clinical trial designed to directly compare the effectiveness of PTNS using Urgent PC to a validated sham intervention over a 12-week period and is a major component of our strategy to expand and support third-party reimbursement coverage of Urgent PC treatments. The investigators' submission of this manuscript was ahead of the original timetable. We fully anticipate submitting an application to the American Medical Association (AMA) for a unique CPT code for PTNS prior to the November 11, 2009 deadline.

"While our fiscal second quarter and first half financial performance is below year-ago results, we are encouraged by the continued strong growth of our U.S. Macroplastique product sales," continued Mr. Kaysen. "Sales of our Macroplastique product in the U.S. through six months of our current fiscal year have about doubled in each quarter over the corresponding year-ago quarter. At the same time, Urgent PC sales in the U.S., while continuing to be challenged by the uncertain insurance reimbursement environment, have stabilized at about $1 million per quarter in each of the last two quarters. While European sales continue to be impacted by a competitive product launch, we saw growth in sales in the second fiscal quarter from distributors in two major European markets which had recorded a decline in the first fiscal quarter. At the same time, with the SUmiT clinical study expenses largely behind us, and our vigilant efforts to manage expenses to conserve cash, we have adequate liquidity to meet our needs for the next 12 months."

Fiscal Second Quarter and First Half Results for the Period Ended September 30, 2009

Net sales for the three months ended September 30, 2009 were $3.0 million versus $3.9 million for the second quarter of fiscal 2009. Net sales for the six months ended September 30, 2009 were $5.8 million versus $8.4 million for same period a year ago.

Net sales to customers in the U.S. during the three months ended September 30, 2009 totaled $1.5 million, as compared to net sales of $2.2 million for the three months ended September 30, 2008. Sales of Urgent PC of $960,000 declined from $2.0 million in the year-ago quarter. The trend in decline of Urgent PC sales over corresponding year-ago periods began in the second half of fiscal 2009 due to reimbursement related issues. Partially offsetting this decline was an increase in Macroplastique product sales to $528,000 from $254,000 in the year-ago quarter. Sales of Macroplastique have steadily increased because of increased sales and marketing focus. Net sales of Macroplastique to customers in the U.S. for the first half of fiscal 2010 totaled $949,000 versus $441,000 for the first six months of fiscal 2009.

Sales to customers outside of the U.S. for the three months ended September, 2009 were $1.5 million, down from $1.7 million in the year-ago period. Excluding the translation impact of fluctuations in foreign currency exchange rates, sales decreased by approximately 5%. The second fiscal quarter is normally the weakest of the year for the Company's international business. The sales decrease as compared to last year is mainly attributed to increased competition from a newly-introduced product competitive with Uroplasty's Macroplastique.

Sales to customers outside of the U.S. for the first half of fiscal 2010 were $2.8 million as compared to $4.0 million, a decrease of 29%, for the six months ended September 30, 2008. Excluding the translation impact of fluctuations in foreign currency exchange rates, sales decreased by approximately 20%. Also contributing to the decline in sales is the discontinuation in the current fiscal year in the U.K. of our I-Stop urethral sling product which accounted for approximately $101,000 in sales for the six months ended September 30, 2009 and $191,000 in sales in fiscal 2009.

Net loss for the second fiscal quarter ended September 30, 2009 was $875,000, or $0.06 per diluted share, versus a net loss of $561,000, or $0.04 per diluted share for the second quarter of last year. For the first half of fiscal 2010, the net loss was $2.2 million, or $0.15 per diluted share as compared with a net loss for the first half of fiscal 2009 of $968,000, or $0.06 per diluted share.

At September 30, 2009, cash and cash equivalents, and short-term investments were $5.8 million compared with $6.3 million at June 30, 2009 and $7.8 million as of March 31, 2009.

"Looking ahead, we expect U.S. sales of Macroplastique to continue to grow during the remainder of the fiscal year as we expect to benefit from our increased sales and marketing effort," continued Mr. Kaysen. "However, we do not expect that we will be able to return to significant sales growth or return to the historic sales level of Urgent PC in the U.S. until a new listed CPT code is assigned and payors create coverage policies that provide adequate reimbursement.

"For the past four quarters we have implemented a comprehensive program designed to educate Medicare carriers and private payer medical directors about the clinical efficacy of Urgent PC. I am pleased with how we have executed this strategy, and we are well ahead of our planned publication and presentation schedule. Phase I OrBIT data, published in September 2009 demonstrated that PTNS had comparable efficacy to the leading anticholinergic drug prescribed for overactive bladder. The data demonstrating sustained symptom improvement at one year from Phase 2 of the OrBIT study has been accepted for publication in the January 2010 edition of The Journal of Urology. With SUmiT study results available in spring 2010, we believe these publications, as well as others, will lead the medical directors to reaffirm or reinstate reimbursement, as well as aid us in our CPT Code application. Our overall goal remains to obtain a unique CPT code that will encourage broader use of Urgent PC. We are confident that we are moving closer toward attaining that goal," Mr. Kaysen concluded.

Conference Call

Uroplasty will host an audio conference call today at 3:30 pm Central, 4:30 pm Eastern, to review the financial results for the second fiscal quarter of 2010. David Kaysen, President and Chief Executive Officer and Medi Jiwani, Vice President, Chief Financial Officer and Treasurer will host the call. Individuals wishing to participate in the conference call should dial 866-561-1721 (domestic) or 480-629-9868 (international). An audio replay will be available for 30 days following the call at 800-406-7325 (domestic) or 303-590-3030 (international), with the passcode 4171526#.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in

The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder.

We also offer Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at

Forward-Looking Information

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. Further, we cannot assure you that our SUmiT clinical trial will produce favorable results, that even if it does produce favorable results third-party payors will provide or continue to provide coverage and reimbursement, or reimburse the providers an amount sufficient to cover their costs and expenses, or that we will timely obtain, or even succeed at all at obtaining, a specific "listed" CPT reimbursement code from the AMA for Urgent PC treatments. We further cannot assure that reimbursement or other issues will not further impact our fiscal 2010 results.

    For Further Information: Uroplasty, Inc.
    David Kaysen, President and CEO, or
    Medi Jiwani, Vice President, CFO, and Treasurer

    EVC Group
    Doug Sherk (Investors)
    Chris Gale (Media)

                           UROPLASTY, INC. AND SUBSIDIARIES


                                Three Months Ended      Six Months Ended
                                   September 30,         September 30,
                                   -------------         -------------
                                 2009        2008        2009       2008
                                 ----        ----        ----       ----

    Net sales                $2,986,475  $3,920,516   $5,812,404   $8,446,138
    Cost of goods sold          535,074     549,199    1,087,044    1,257,166
                                -------     -------    ---------    ---------

    Gross profit              2,451,401   3,371,317    4,725,360    7,188,972
                              ---------   ---------    ---------    ---------

    Operating expenses
       General and
        administrative          713,040     918,394    1,561,591    1,957,108
       Research and
        development             435,898     327,978      963,713      733,498
       Selling and marketing  1,968,054   2,505,598    4,025,342    5,125,632
       Amortization             211,503     210,966      423,316      421,941
                                -------     -------      -------      -------
                              3,328,495   3,962,936    6,973,962    8,238,179
                              ---------   ---------    ---------    ---------

    Operating loss             (877,094)   (591,619)  (2,248,602)  (1,049,207)
                               --------    --------   ----------  -----------

    Other income
       Interest income           24,230      63,542       55,629      138,656
       Interest expense          (1,788)     (6,750)      (9,694)     (13,585)
       Foreign currency
        exchange gain (loss)     (7,365)      5,038      (14,697)        (732)
       Other, net                 2,000      (4,687)        (183)      (4,687)
                                  -----      ------         ----       ------
                                 17,077      57,143       31,055      119,652
                                 ------      ------       ------      -------

    Loss before income
     taxes                     (860,017)   (534,476)  (2,217,547)    (929,555)

    Income tax expense           14,642      26,487       22,887       38,057
                                 ------      ------       ------       ------

    Net loss                  $(874,659)  $(560,963) $(2,240,434)   $(967,612)
                              =========  ==========  ===========    =========

    Basic and diluted
     loss per common
     share                       $(0.06)     $(0.04)      $(0.15)      $(0.06)

    Weighted average
     common shares
       Basic and diluted     14,946,540  14,916,540   14,942,179   14,916,540

                           UROPLASTY, INC. AND SUBSIDIARIES


                                                   September 30,  March 31,
                                                       2009         2009
                                                     ----------  ----------
       Current assets:
           Cash and cash equivalents & Short-term
            investments                              $5,792,867  $7,776,299
           Accounts receivable, net                   1,196,518   1,214,049
           Inventories                                  486,269     495,751
           Other                                        326,278     279,898
                                                        -------     -------
                  Total current assets                7,801,932   9,765,997

       Property, plant, and equipment, net            1,389,493   1,401,229
       Intangible assets, net                         2,955,332   3,378,648
       Prepaid pension asset                             86,687      66,130
       Deferred tax assets                               79,367      68,793
                                                         ------      ------
             Total assets                           $12,312,811 $14,680,797
                                                    =========== ===========
    Liabilities and Shareholders' Equity
       Current liabilities:
               Current portion - deferred rent          $35,000     $35,000
           Accounts payable                             431,016     604,593
               Income tax payable                             -      56,785
           Accrued liabilities                          902,718   1,231,620
                                                        -------   ---------
                Total current liabilities             1,368,734   1,927,998

       Deferred rent - less current portion             130,114     147,576
       Accrued pension liability                        283,008     296,646
                                                        -------     -------

       Total liabilities                              1,781,856   2,372,220
                                                      ---------   ---------

       Total shareholders' equity                    10,530,955  12,308,577
                                                     ----------  ----------

       Total liabilities and shareholders' equity   $12,312,811 $14,680,797
                                                    =========== ===========

                           UROPLASTY, INC. AND SUBSIDIARIES


                                                      Six Months Ended
                                                        September 30,
                                                   2009                2008
                                                   ----                ----
    Cash flows from operating
       Net loss                             $(2,240,434)          $(967,612)
            Adjustments to reconcile
             net loss to net cash used
             in operating activities:
            Depreciation and
             amortization                       567,238             566,949
            Loss on disposal of
              equipment                             186               4,687
            Share-based consulting
             expense                                  -              36,409
            Share-based compensation
             expense                            291,462             453,592
            Deferred income taxes                (3,249)            (10,164)
                             Deferred rent      (17,500)            (17,500)
            Changes in operating assets
             and liabilities:
                Accounts receivable              91,206             537,959
                Inventories                      47,499             (11,128)
                Other current assets and
                 income tax receivable         (102,998)           (108,041)
                Accounts payable               (185,406)           (145,610)
                Accrued liabilities            (348,381)           (634,851)
                Accrued pension liability,
                 net and income tax payable     (58,492)            (44,772)
                                                -------             -------
    Net cash used in operating
     activities                              (1,958,869)           (340,082)
                                             ----------            --------

    Cash flows from investing
       Proceeds from sale of
        short-term investments                2,500,000           8,808,304
       Purchase of short-term
        investments                          (2,000,000)         (7,891,373)
       Purchases of property,
        plant and equipment                     (61,334)           (130,421)
       Proceeds from sale of
        property, plant and
        equipment                                 2,000                   -
                                                  -----                 ---
    Net cash provided by
     investing activities                       440,666             786,510
                                                -------             -------

    Cash flows from financing
       Repayment of debt
        obligations                                   -            (455,913)
                                                    ---            --------
    Net cash used in financing
     activities                                       -            (455,913)
                                                    ---            --------

    Effect of exchange rates on
     cash and cash equivalents                   34,771            (194,967)
                                                 ------            --------

    Net decrease  in cash and
      cash equivalents                       (1,483,432)           (204,452)

    Cash and cash equivalents
     at beginning of period                   3,276,299           3,880,044
                                              ---------           ---------

    Cash and cash equivalents
     at end of period                        $1,792,867          $3,675,592
                                             ==========          ==========

    Supplemental disclosure of
     cash flow information:
       Cash paid during the period
        for interest                             $6,145             $13,612
       Cash paid during the period
        for income taxes                        105,877              35,474

Non-GAAP Financial Measures: The following table reconciles our financial results calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, and depreciation and amortization expenses from gross profit, operating expenses and operating loss. The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP. We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies. Therefore, our non-GAAP financial measures may not be comparable to those used by other companies. We have described the reconciliations of each of our non-GAAP financial measures above to the most directly comparable GAAP financial measures.

We use these non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes because we believe such measures are one important indicator of the strength and the performance of our business as they provide a link to operating cash flow. We also believe that analysts and investors use such measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Our non-GAAP operating loss of approximately $475,000 for the three months ended September 30, 2009 was greater than the $98,000 operating loss in same period in fiscal 2009. Our non-GAAP operating loss was approximately $1,390,000 for the six months ended September 30, 2009 compared to an operating income of $8,000 in same period fiscal in 2009. We attribute the increased operating loss primarily to the decrease in sales and a lower gross margin rate, offset partially by a decrease in cash operating expenses.

                            Three Months Ended             Six Months Ended
                               September 30,                 September 30,
                               -------------                 -------------
                             2009              2008         2009         2008
                             ----              ----         ----         ----
    Gross Profit
       GAAP gross
        profit         $2,451,401        $3,371,317   $4,725,360   $7,188,972
            % of sales         82%               86%          81%          85%
        compensation        4,903             8,879       18,448       25,253
        expense            14,150            13,057       28,299       25,847
                           ------            ------       ------       ------
        gross profit    2,470,454         3,393,253    4,772,107    7,240,072
                        ---------         ---------    ---------    ---------

        expenses        3,328,495         3,962,936    6,973,962    8,238,179
        compensation      113,909           198,131      273,014      464,748
        expense            57,546            62,104      115,623      119,161
        expense           211,503           210,966      423,316      421,941
                          -------           -------      -------      -------
        expenses        2,945,537         3,491,735    6,162,009    7,232,329
                        ---------         ---------    ---------    ---------

        loss             (877,094)         (591,619)  (2,248,602)  (1,049,207)
        compensation      118,812           207,010      291,462      490,001
        expense            71,696            75,161      143,922      145,008
        expense           211,503           210,966      423,316      421,941
                          -------           -------      -------      -------
        (loss)          $(475,083)         $(98,482) $(1,389,902)      $7,743
                        ---------          --------  -----------       ------

SOURCE Uroplasty, Inc.

SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
2. Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial
3. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
4. Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... , ... Safe storage for contraceptive devices may not always be easy to ... and the other from Bradley Beach, New Jersey, there is an easy solution to ... to replace NuvaRings more often than necessary. As such, it affords peace of mind ...
(Date:11/27/2015)... Canada (PRWEB) , ... November 28, 2015 , ... There ... do we outperform our billings from last year? , This question has not been ... organizations are coming to the retirement age and the younger workforce don’t share the ...
(Date:11/27/2015)... ... 2015 , ... The rapid speed at which Americans are ... care is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming more ... forgotten part of this equation: 80 percent of medical care occurs in the ...
(Date:11/27/2015)... County, CA (PRWEB) , ... November 27, 2015 , ... ... season , The company is offering customers 10% off of their purchase of lice ... any treatment at full price. According to a company spokesperson. “Finding lice is a ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent ... sharing, the 2016 Building Better Radiology Marketing Programs meeting will showcase ... Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference ...
Breaking Medicine News(10 mins):